99 related articles for article (PubMed ID: 20022492)
1. Design and synthesis of novel bis-oximinoalkanoic acids as potent PPAR alpha agonists.
Pingali H; Jain M; Shah S; Zaware P; Makadia P; Pola S; Thube B; Patel D; Patil P; Priyadarshini P; Suthar D; Shah M; Giri S; Patel P
Bioorg Med Chem Lett; 2010 Feb; 20(3):1156-61. PubMed ID: 20022492
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.
Pingali H; Jain M; Shah S; Makadia P; Zaware P; Goel A; Patel M; Giri S; Patel H; Patel P
Bioorg Med Chem; 2008 Aug; 16(15):7117-27. PubMed ID: 18625559
[TBL] [Abstract][Full Text] [Related]
3. Novel oxazole containing phenylpropane derivatives as peroxisome proliferator activated receptor agonists with hypolipidemic activity.
Pingali H; Raval S; Raval P; Makadia P; Zaware P; Goel A; Suthar D; Jain M; Patel P
Pharmazie; 2008 Jul; 63(7):497-502. PubMed ID: 18717481
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Aoki T; Asaki T; Hamamoto T; Sugiyama Y; Ohmachi S; Kuwabara K; Murakami K; Todo M
Bioorg Med Chem Lett; 2008 Mar; 18(6):2128-32. PubMed ID: 18280733
[TBL] [Abstract][Full Text] [Related]
5. Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety.
Pingali H; Jain M; Shah S; Patil P; Makadia P; Zaware P; Sairam KV; Jamili J; Goel A; Patel M; Patel P
Bioorg Med Chem Lett; 2008 Dec; 18(24):6471-5. PubMed ID: 18976908
[TBL] [Abstract][Full Text] [Related]
6. Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.
Shi GQ; Dropinski JF; Zhang Y; Santini C; Sahoo SP; Berger JP; Macnaul KL; Zhou G; Agrawal A; Alvaro R; Cai TQ; Hernandez M; Wright SD; Moller DE; Heck JV; Meinke PT
J Med Chem; 2005 Aug; 48(17):5589-99. PubMed ID: 16107159
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Asaki T; Aoki T; Hamamoto T; Sugiyama Y; Ohmachi S; Kuwabara K; Murakami K; Todo M
Bioorg Med Chem; 2008 Jan; 16(2):981-94. PubMed ID: 17964792
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of potent and subtype-selective PPARalpha agonists.
Desai RC; Metzger E; Santini C; Meinke PT; Heck JV; Berger JP; MacNaul KL; Cai TQ; Wright SD; Agrawal A; Moller DE; Sahoo SP
Bioorg Med Chem Lett; 2006 Mar; 16(6):1673-8. PubMed ID: 16384704
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.
Devasthale PV; Chen S; Jeon Y; Qu F; Shao C; Wang W; Zhang H; Cap M; Farrelly D; Golla R; Grover G; Harrity T; Ma Z; Moore L; Ren J; Seethala R; Cheng L; Sleph P; Sun W; Tieman A; Wetterau JR; Doweyko A; Chandrasena G; Chang SY; Humphreys WG; Sasseville VG; Biller SA; Ryono DE; Selan F; Hariharan N; Cheng PT
J Med Chem; 2005 Mar; 48(6):2248-50. PubMed ID: 15771468
[TBL] [Abstract][Full Text] [Related]
10. Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists.
Grether U; Bénardeau A; Benz J; Binggeli A; Blum D; Hilpert H; Kuhn B; Märki HP; Meyer M; Mohr P; Püntener K; Raab S; Ruf A; Schlatter D
ChemMedChem; 2009 Jun; 4(6):951-6. PubMed ID: 19326383
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
Li Z; Liao C; Ko BC; Shan S; Tong EH; Yin Z; Pan D; Wong VK; Shi L; Ning ZQ; Hu W; Zhou J; Chung SS; Lu XP
Bioorg Med Chem Lett; 2004 Jul; 14(13):3507-11. PubMed ID: 15177462
[TBL] [Abstract][Full Text] [Related]
12. Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification.
Zaware P; Shah SR; Pingali H; Makadia P; Thube B; Pola S; Patel D; Priyadarshini P; Suthar D; Shah M; Jamili J; Sairam KV; Giri S; Patel L; Patel H; Sudani H; Patel H; Jain M; Patel P; Bahekar R
Bioorg Med Chem Lett; 2011 Jan; 21(2):628-32. PubMed ID: 21195611
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
Shi GQ; Dropinski JF; McKeever BM; Xu S; Becker JW; Berger JP; MacNaul KL; Elbrecht A; Zhou G; Doebber TW; Wang P; Chao YS; Forrest M; Heck JV; Moller DE; Jones AB
J Med Chem; 2005 Jun; 48(13):4457-68. PubMed ID: 15974597
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists.
Zhang H; Ryono DE; Devasthale P; Wang W; O'Malley K; Farrelly D; Gu L; Harrity T; Cap M; Chu C; Locke K; Zhang L; Lippy J; Kunselman L; Morgan N; Flynn N; Moore L; Hosagrahara V; Zhang L; Kadiyala P; Xu C; Doweyko AM; Bell A; Chang C; Muckelbauer J; Zahler R; Hariharan N; Cheng PT
Bioorg Med Chem Lett; 2009 Mar; 19(5):1451-6. PubMed ID: 19201606
[TBL] [Abstract][Full Text] [Related]
16. (2R)-2-methylchromane-2-carboxylic acids: discovery of selective PPARalpha agonists as hypolipidemic agents.
Koyama H; Boueres JK; Miller DJ; Berger JP; MacNaul KL; Wang PR; Ippolito MC; Wright SD; Agrawal AK; Moller DE; Sahoo SP
Bioorg Med Chem Lett; 2005 Jul; 15(14):3347-51. PubMed ID: 15950464
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.
Yamazaki Y; Abe K; Toma T; Nishikawa M; Ozawa H; Okuda A; Araki T; Oda S; Inoue K; Shibuya K; Staels B; Fruchart JC
Bioorg Med Chem Lett; 2007 Aug; 17(16):4689-93. PubMed ID: 17553678
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo.
Kane CD; Stevens KA; Fischer JE; Haghpassand M; Royer LJ; Aldinger C; Landschulz KT; Zagouras P; Bagley SW; Hada W; Dullea R; Hayward CM; Francone OL
Mol Pharmacol; 2009 Feb; 75(2):296-306. PubMed ID: 18971326
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and identification of [1,2,4]thiadiazole derivatives as a new series of potent and orally active dual agonists of peroxisome proliferator-activated receptors alpha and delta.
Shen L; Zhang Y; Wang A; Sieber-McMaster E; Chen X; Pelton P; Xu JZ; Yang M; Zhu P; Zhou L; Reuman M; Hu Z; Russell R; Gibbs AC; Ross H; Demarest K; Murray WV; Kuo GH
J Med Chem; 2007 Aug; 50(16):3954-63. PubMed ID: 17608467
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor alpha agonists.
Faucher N; Martres P; Laroze A; Pineau O; Potvain F; Grillot D
Bioorg Med Chem Lett; 2008 Jan; 18(2):710-5. PubMed ID: 18060776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
